The Global Ascites Market was valued at USD 23,556 million in 2024 and is expected to reach USD 37,627 million by 2033, at a CAGR of 4.78% during the forecast period 2024 – 2033.
Ascites Market: Overview
The prevalence of Ascites disease is increasing across the globe due to increasing the fluids in the abdomen belly. Ascites cause various symptoms such as bloating, increased weight, shortness of breath, increasing abdomen size, abdominal discomfort and excessive swelling.
Various factors, such as the growing number of chronic disease patients, increasing cases of heart failure, growing prevalence of liver cirrhosis, increasing cancer patients, growing geriatric population, increasing disposable income coupled with growing healthcare awareness, are mainly driving the market growth of ascites during the forecast period.
Key players operating in the market are collaborating with many drug research institutes and end-user industries to foster research and innovations in ascites diagnosis and treatments, which is expected to create lucrative opportunities for the market during the forecast period. An increasing number of hospitals and the growing emergence of E-commerce channels for the distribution of medicines across the globe are expected to create lucrative opportunities for the market during the forecast period.
Key trends observed in the market include the growing usage of emerging technologies and the increasing use of generic drugs to treat ascites, setting new trends in the global ascites market. For instance, many end users and key players are using machine learning, artificial intelligence, and advanced ultrasound technologies to detect, treat, and diagnose ascites. Such factors are expected to create lucrative opportunities for the market during the forecast period.
However, the high diagnostic cost of ascites, the lack of skilled expertise in diagnosing ascites, the low availability of treatments in many underdeveloped countries, and the lack of proper treatments for ascites are some factors restraining the market growth.
The global Ascites market is segmented by type, diagnosis, route of administration, end user and region. By Type, the transudate segment dominated the global market in 2023 and is expected to keep its dominance during the forecast period owing to the growing number of transudate ascites patients across the globe. The transudate fluid is normal and spreads on the peritoneal surface. It is low in protein and is formed commonly due to an increase in portal pressure by the Starling hypothesis.
By region, North America dominated the global Ascites market and is expected to maintain its dominance during the forecast period owing to growing investment and many technology giants in this region. Various factors such as well-established healthcare and pharmaceutical industry, increasing number of liver cirrhosis patients and increasing innovations in the ascites diagnosis industry are mainly driving the market growth of this region during the forecast period. Key countries, such as the U.S., Canada, and Mexico, are expected to drive the market growth of this region during the forecast period.
Report Scope
| Feature of the Report | Details |
| Market Size in 2024 | USD 23,556 Million |
| Projected Market Size in 2033 | USD 37,627 Million |
| Market Size in 2023 | USD 22,670 Million |
| CAGR Growth Rate | 4.78% CAGR |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Key Segment | By Types, Diagnosis, Treatment, Route of Administration, End-Users, Distribution Channel and Region |
| Report Coverage | Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends |
| Regional Scope | North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America |
| Buying Options | Request tailored purchasing options to fulfil your research requirements. |
CMI has comprehensively analyzed the Ascites market. The driving forces, restraints, challenges, opportunities, and key trends have been explained in depth to depict an in-depth market scenario. Segment-wise market size and market share during the forecast period have been duly addressed to portray the probable picture of this Global Ascites industry.
The competitive landscape includes key innovators, after-market service providers, market giants, and niche players, who are studied and analyzed extensively with respect to their strengths, weaknesses, and value-adding prospects. In addition, this report covers key players’ profiles, market shares, mergers and acquisitions, consequent market fragmentation, and new trends and dynamics in partnerships.
List of the prominent players in the Ascites Market:
- Hoffmann-La Roche Ltd.
- AstraZeneca
- GSK plc
- Johnson & Johnson Private Limited
- Lilly
- Merck & Co. Inc.
- Mylan N.V.
- Novartis AG
- Pfizer Inc.
- Sanofi
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- WOCKHARDT
- BioVie Inc.
- Fresenius SE & Co. KGaA
- Sequana Medical NV
- BD
- Medtronic
- PharmaCyte Biotech Inc.
- GI Supply
- Others
The Ascites Market is segmented as follows:
By Types
- Transudative
- Exudative
- Others
By Diagnosis
- Ultrasound
- CT Scan
- MRI
- Blood Test
- Laparoscopy
- Angiography
- Others
By Treatment
- Medication
- Paracentesis
- Surgery
- Others
By Route of Administration
- Oral
- Parenteral
- Others
By End-Users
- Hospitals
- Homecare
- Specialty Clinics
- Others
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacies
- Others
Regional Coverage:
North America
- U.S.
- Canada
- Mexico
- Rest of North America
Europe
- Germany
- France
- U.K.
- Russia
- Italy
- Spain
- Netherlands
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Taiwan
- Rest of Asia Pacific
The Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of the Middle East & Africa
Latin America
- Brazil
- Argentina
- Rest of Latin America